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1. Introduction
Gene therapy, the therapeutic transfer of genetic information to a target cell, continues to be a
promising alternative in the fight against cancer. In the case of melanoma, the use of an
experimental treatment is justified since this disease is incurable in its advanced stages. Is gene
therapy a viable option for the treatment of melanoma patients? In this chapter, we will attempt
to answer this question by exploring the intersection between the technology of gene therapy
and the biology of melanoma, a point at which opportunities for intervention are revealed.
The technology of gene therapy depends on our ability to create a vehicle that will deliv‐
er the therapeutic payload to the target cell. Today, a variety of vectors are available that
have the capacity to encode a therapeutic gene or sequences that are capable of blocking
gene expression, such as RNA interference (RNAi). The technology of viral and non-viral
vectors  will  be  discussed.  Viral  vectors  offer  the  benefit  of  using  existing  biological
mechanisms  in  order  to  enter  the  target  cell.  However,  when  choosing  a  gene  transfer
vehicle,  viral  vectors  must  be  carefully  considered  since  each  option  will  present  a
unique profile of advantages and disadvantages, especially as related to the efficiency of
the virus in reaching the target cell and in the vector’s propensity to activate an immune
response. Alternatively, non-viral vectors, such as plasmids, offer the advantage of safety
and ease of manipulation, but may require the use of physical or chemical agents in or‐
der to pass the through the cytoplasmic membrane and enter the cell.
With these gene transfer tools in hand, now we can turn our attention to the options for
the therapeutic gene which will be inserted in the vector. Strategies for cancer gene ther‐
apy  are  many,  but  share  the  common goal  of  inhibiting  or  destroying  the  tumor  cells.
This may be accomplished by the use of pro-apoptic genes, tumor suppressor genes, sui‐
cide genes or immune-modulating genes (among many other options). In fact, the thera‐
peutic sequence need not be a gene at all, but instead the RNAi system can be employed
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to block the expression of critical genes that contribute to tumor progression. Moreover,
the gene therapy strategy need not be performed directly in the tumor cells, but may be
applied to components of the immune system, such as T-cells or dendritic cells, that will
then carry out the anti-tumor activity.
The biology of melanoma presents several opportunities as well as challenges for its treatment
by gene therapy approaches. In particular, the high metastatic potential of late stage melanoma
represents one of these challenges. Is it realistic to expect that a virus delivered to the primary
treatment site will have an effect on distant or even not yet identified metastatic sites? The use
of a replicating virus may overcome this barrier since these ‘oncolytic’ vectors, which multiply
only in tumor cells, can spread from cell to cell. In addition, melanoma is considered to be an
immunogenic tumor, opening the possibility of generating tumor reactive immune cells with
the assistance of gene transfer technology. As an alternative to established modalities,
biochemotherapy may be reincarnated in the form of gene transfer of cytokines or interferons.
Some cutting edge research efforts include the development of oncolytic viruses that are armed
with an immune-modulating gene, creating a double-edged anti-tumor agent.
A growing body of pre-clinical work supports the notion that gene therapy may be a valuable
strategy for the treatment of melanoma. To date, quite a few clinical trials of menaloma gene
therapy have been performed. With the advances in our understanding of both the technology
of gene therapy and the biology of melanoma, we propose that an increasing number of these
experimental approaches will reach phase III trials and be offered to a growing number of
these patients who have such limited therapeutic options.
2. Gene therapy progress and pitfalls
For more than 20 years now, gene therapy has been applied in more than 1840 clinical trials
for the treatment of a great variety of indications (Journal of Gene Medicine’s Gene Therapy
Clinical Trials Worldwide, http://www.wiley.com/legacy/wileychi/genmed/clinical). Among
these trials, cancer represents the disease most commonly treated by therapies that include a
gene transfer component. Currently, only a few gene therapy products have been approved
for commercialization (Table 1) and the USA has yet to approve any such treatments.
The first gene therapy clinical trial was performed in the USA in 1990. This trial used an ex
vivo approach where gammaretrovirus was employed to transfer a normal copy of the
adenosine deaminase (ADA) gene to peripheral T-cells in two young patients suffering from
severe combined immunodeficiency (SCID) due to the lack of ADA function (ADA-SCID) [7].
Neither of the treated patients exhibited any adverse effects and one had clinical benefit lasting
well over a decade [8]. Since then, gene therapy for ADA-SCID has evolved and now uses ex
vivo genetic modification of hematopoietic stem cells resulting in proper immune function,
adenosine metabolism and no need for further treatment in 21 of 31 patients, none of whom
showed adverse effects [9].
A similar approach for the treatment of SCID-X1 (SCID due to a mutated IL2RG gene, the
common IL2 receptor gamma chain) and 18 of 20 patients have had their immune system
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restored. Unfortunately, 5 of these children developed leukemia due, in part, to the presence
of the therapeutic virus in the patients’ genome. Though 4 were successfully treated with
chemotherapy, one patient did succumb to the leukemia [9]. Many important lessons were
learned from the SCID trials, including the fact that the same vector can be innocuous in one
situation (ADA-SCID), yet dangerous in another (SCID-X1). The SCID-X1 trials were more
successful in achieving long term benefit (90% vs. 70%) and were less likely to provoke an
adverse effect (25% vs. 50%) when comparing the traditional treatment (allogenic bone marrow
transplant in particular) and gene therapy, respectively [9]. Efforts are underway to use
alternative vectors, such as lentivirus, that should be safer and should not provoke the side
effects seen with the gammaretroviral vectors.
Local
(year/agency)
Company Vector Description References
China (2003/
SFDA)
Shenzhen
Gentech
SiBiono
Gendicine (Ad-
p53)
Non-replicating adenoviral vector
expressing wild-type p53 for the
treatment of head and neck cancer.
[1, 2]
China (2005/
SFDA)
Shanghai
Sunway
Biotech
Oncorine/H101
(Onyx-015)
Conditionally replicating adenovirus
containing a mutant E1b protein
which confers tumor-specific
oncolysis. Approved for treatment of
head and neck cancers.
[1, 2]
Phillipines (2007/
BFAD)
Epeius Rexin-G* Replication-incompetent retrovector
targeted to the tumor matrix
(collagen) and expressing a cyclin-g
mutant that induces cell death.
Approved for treatment of all solid
tumors.
[3, 4]
European Union
(2012/EMA-
CHMP**)
Amsterdam
Molecular
Therapeutics
Glybera
(alipogene
tiparvovec)
Adeno-associated virus encoding the
Ser(447)X variant of human
lipoprotein lipase (LPL) gene for the
treatment of familial LPL deficiency.
[5, 6]
*Orphan drug status approved by FDA in 2008 **Approval finalized in late 2012; orphan drug status granted in
2004.SFDA, State Food and Drug Administration of China; BFAD, Bureau of Food and Drugs; EMA-CHMP, European
Medicines Agency-Committee for Medicinal Products for Human Use; FDA, Food and Drug Administration, USA
Table 1. Gene therapy products approved for commercial distribution.
Genetic modification of hematopoietic stem cells has also been explored for the treatment of
β-thalessemia, Wiskott Aldrich Syndrome, adrenoleukodystrophy and chronic granuloma‐
tous disease [9, 10]. These trials were generally considered to be successful with respect to
clinical benefit of the treatment, yet only the treatment of ALD was free from unwanted cellular
proliferation due to the presence of the therapeutic virus. The field continues to evolve and
the need for better vectors and a better understanding of their biology is warranted.
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Other examples of successful gene therapy have been reported for the treatment of Leber’s
congenital amaurosis, a genetic alteration that leads to blindness. Several groups have
transferred a normal copy of the affected gene, HPE65, to the retina using adeno-associated
virus. Of the 18 patients originally treated, many have gained visual acuity and are able to
identify shapes and even navigate obstacle courses that were impassable before treatment. In
general, these patients first received monocular therapy, but, due to the success of the treat‐
ment, several have since been treated in the contralateral eye. The effectiveness of the second
treatment was significant since clinical benefit was achieved and re-inoculation of the virus
was not blocked by nor did it provoke any unwanted immune response [11].
In 1999, Jessie Gelsinger, a young patient with ornithine transcarbamylase deficiency received
a massive dose of adenovirus as part of his gene therapy. Unfortunately, he suffered a strong
immune reaction, entered anaphylactic shock and died [10]. Though this case did spark quite
a bit of controversy and contributed to the negative public opinion of gene therapy, it does
serve as a reminder of how new, experimental and unexplored aspects of gene therapy require
continued re-evaluation. In this introduction, we have attempted to present a balanced
description of the progress and pitfalls noted in gene therapy trials. Note that of the thousands
of patients treated with gene therapy world-wide, we know of only 10 or so cases of serious
adverse effects due to the gene therapy agent (the virus). When we consider the cost, time,
morbidity and mortality associated with the development of many of the currently accepted
(‘traditional’) treatments, such as bone marrow transplantation and chemotherapy, we see that
gene therapy is still in its initial phases, yet many of the benefits do outweigh the risks.
3. Vectors: General concepts
The concept behind gene therapy is really quite simple: introduce genetic material into cells
with the aim of inducing a clinically beneficial activity. The process of gene transfer generally
requires a vector, or vehicle, to deliver the genetic payload to the target cell. In basic terms,
this can be accomplished by either viral or non-viral vectors. Some 65% of clinical trials have
relied on viral vectors while 35% used non-viral vectors, including plasmids and RNA (http://
www.wiley.com/legacy/wileychi/genmed/clinical/). The principal advantage to using re‐
combinant viral vectors is that their naturally occurring counterparts have already developed
mechanisms for reaching and entering cells. This point is also their downfall, since our bodies
have also evolved anti-viral defense mechanisms. Since plasmid vectors are essentially free of
antigens and since their sequence can be carefully controlled, they are much less likely to
provoke an immune response. Many cell types, but especially muscle, are quite efficiently
transfected by plasmids.
Selecting a gene transfer vector depends greatly on the therapeutic approach (ex vivo or in
situ), the required duration of transgene expression (for example, long term for immunodefi‐
ciencies and metabolic disorders, but short term for cancer), the disease and cell type in
question (proliferating or post-mitotic, stem cell or differentiated, etc) and the characteristics
of the transgene itself (the length of the cDNA, secretion of the protein product, requirement
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for expression in a specific tissue or under a particular physiologic condition). Some of the
more popular gene transfer vectors are described in Figure 1 and Table 2.
Figure 1. Schematic representation of the wild type counterpart of the typically used recombinant viral vectors. (A)
Gammaretroviruses and (B) lentiviruses share similar structures, but differ greatly in their genomes and their impact on
cellular function. Gag, pro, pol and env genes encode structural proteins of the capsid, protease, reverse transcriptase
and envelope proteins, respectively. The additional lentiviral genes perform regulatory functions as well as alter cellu‐
lar function. (C) The serotype 5 adenovirus has a protein capsid (non-enveloped) and a large, complex genome that
encodes critical genes for viral replication (E1a, E1b) as well as structural and functional genes that regulate both viral
and cellular activities.
In the laboratory, viral vectors are typically manipulated in the form of plasmids that encode
the genome to be packaged in the viral progeny (including the gene of interest and regulatory
elements that control its expression) as well as information for the generation of a functional
virus particle. In general, viral vectors are engineered so that they are incapable of replicating
outside of the laboratory. In other words, they can be produced in the lab, but do not form an
active infection in patients, thus limiting their horizontal spread. Replication deficient viruses
are capable of entering a target cell and expressing the therapeutic gene, but do not carry
enough genetic information to form the next generation of virus, a process best referred to as
transduction.
Plasmid vectors are much simpler from a technological point of view and come with the benefit
of residing in the cell as an episome and being poorly immunogenic. Some considerations
when using plasmids include vector design and delivery. Since cells do not actively take up
plasmids, it would seem that their utility as a gene transfer vector would be limited. In reality,
muscle cells are quite permissive to transfection even when ‘naked’ plasmid DNA is applied.
When complexed to chemical carriers and/or in combination with physical methods of
transfection, a great many tissues can be treated with plasmids (or even oligos, siRNA, RNA,
etc). Non-viral vectors, therefore, offer certain advantages over recombinant viruses.
Vector targeting can be performed at either the transcriptional or transductional level. In
theory, targeting would present the advantage of promoting gene transfer in the cell of interest
and avoiding ‘off target’ effects. In this way, normal healthy cells would be spared and the
treatment would be directed to the appropriate cell. Vector targeting should increase safety
and efficiency of the treatment. Transductional targeting directs the virus to a specific cell type
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and should reduce the number of off target cells that are transduced. In other words, the virus
should reach only the desired cell type. Such vectors are engineered so that that viral proteins
are able to interact with specific cellular receptors present only (or principally) on the target
cell. Transcriptional targeting involves the use a promoter that is active only in the desired cell
type or only under specific physiologic conditions. Cancer cells offer many distinctions that
benefit transcriptional targeting, such as expression of hTert or survivin, proliferation (which
is typically associated with E2F1 activity) and stabilization of HIF1α under hypoxic conditions.
Transcriptional targeting does not restrict which cells will be transduced, but does determine
where the vector will be allowed to express the transgene. These strategies can also be
combined, thus increasing the degree of specificity.
Vector Gammaretrovirus Lentivirus Adenovirus Adenoassociated
Virus
Non-viral (plasmid,
naked and
lipofection)
Titer, virus
particles/mla
109 109 1012 1012 NA
Route of
delivery
Ex vivo Ex vivo In situ In situ In situ
Integration in
the host
genome
Yes Yes No Yes/No No
Long term
expression
Yes Yes No Yes No
Immune
response to
viral proteins
No No Yes Yes, but less severe No
Clinical trialsb 370 55 438 92 456
Typical clinical
application
Hematopoietic
system
Hematopoiet
ic system
Cancer,
vaccines,
vascular
diseases
Hemophilia, cystic
fibrosis
Cardiovascular,
cancer, vaccines
a: titer after concentration of virus preparation
b: trials listed on http://www.wiley.com/legacy/wileychi/genmed/clinical/
NA, not applicable
Table 2. Properties of vectors commonly used in clinical gene therapy trials
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4. Vectors: Retrovirus
Gene transfer vectors derived from retroviruses have played an important role in the devel‐
opment of current gene therapy approaches. As mentioned above, a retroviral vector (derived
from Moloney Murine Leukemia Virus, MoMLV) was the first to be used in an FDA-sanctioned
clinical trial, retroviral vectors are the second most popular viral vector and are the vector of
choice for ex vivo gene transfer approaches (Table 2).
To be clear, we use the term ‘retrovirus’ to describe all viruses belonging to the retroviri‐
dae family,  though we will  be focusing on gammaretrovirus (the genus which includes
MoMLV) and lentivirus (the genus that includes HIV). These wild-type viruses are close‐
ly related and share many features, such as a capsid that is enveloped in a lipid bilayer
and which carries  two copies  of  the  viral  genome in  the  form of  single  stranded RNA
(Figure  1).  When  the  virus  envelope  protein  interacts  with  its  cognate  receptor  on  the
cell  surface,  the  viral  and  cellular  membranes  fuse,  the  capsid  is  internalized  and  the
RNA strands are liberated in the cytoplasm (Figure 2).  The process of reverse transcrip‐
tion  generates  a  dsDNA copy of  the  viral  genome which  then must  gain  access  to  the
nucleus  before  integrating  at  an  essentially  random  position  in  one  of  the  host  cell’s
chromosomes.  The  DNA  copy  of  the  gammaretroviral  genome  gains  access  to  the  cell
nucleus only upon cell  division,  when the nuclear envelope is  dismantled.  For this  rea‐
son, gammaretroviruses can only infect dividing cells. In contrast, lentiviral DNA passes
through the nuclear membrane by an active process that is unrelated to cell  division. In
other  words,  lentiviruses  are  able  to  infect  both  dividing  and  non-dividing  cells.  Once
the  retroviral  genome has  been  integrated  in  the  host  DNA,  it  is  then  referred  to  as  a
provirus. Viral gene expression and viral replication result from the information encoded
by the provirus.  Virus progeny bud from the cell  surface,  a process that does not harm
the host cell [12].
The recombinant versions of retroviral vectors follow the form and function of their wild-type
counterparts, but modifications are engineered in the vectors to improve safety and tropism.
In general terms, a plasmid (transfer vector) is used to encode the sequence (including the gene
of interest) that will be encapsulated in the virus particle and separate plasmids (packaging
constructs) are used to encode the proteins that make up the virus structure (Figure 3). A
sequence in the viral genome, called ψ, directs encapsidation of the viral RNA. This signal is
present in the transfer vector, but not in the packaging constructs, thus the information for
generating a new particle is not carried by the progeny, but the gene of interest is. Since the
virus progeny do not carry the genes necessary to form a new particle, viral replication does
not occur in the transduced cell and serves as a safety mechanism [12].
The tropism of the retroviral vector is determined principally by its envelope protein. Through
engineering of the packaging constructs, the native envelope protein can be exchanged for an
alternate protein that provides adequate tropism. For gammaretroviral vectors, ample tropism
is provided by the 10A1 amphotropic envelope protein, though other options do exist. For
lentivirus, the native envelope proteins direct transduction of CD4 and/or CCR5 positive cells.
This would be too limited for most gene transfer efforts. Instead, the lentiviral envelope is
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typically replaced with the envelope glycoprotein from Vesicular Stomatitis Virus (VSVg).
Since VSVg interacts with heparin, a ubiquitous component of the cell membrane, such
‘pseudotyped’ vectors can transduce most any cell type. The VSVg envelope can also be used
to pseudotype gammaretroviral vectors [12, 13].
Figure 2. Schematic representation of the retroviral lifecycle. Though a gammaretrovirus is depicted, this process is
quite similar for lentiviruses. (1) The retroviral envelope protein interacts with a cellular receptor and membranes are
fused. (2) The capsid is internalized and (3) the viral genome, in the form of RNA, is liberated. (4) Reverse transcription
results in the generation of a dsDNA copy of the viral genome which then must reach the nucleus (5), a process that
for gammaretrovirus requires cell division since the viral DNA is not actively transported across the nuclear membrane,
yet lentiviral DNA is and therefore does not require cell division for nuclear import. Once in the nucleus, the viral DNA
is inserted in the host genome and is now referred to as a provirus. (6) Expression of the viral genes from the provirus
provides all the components necessary for the assembly of progeny which then bud from the cell surface (7).
Retroviral vectors are not efficient vehicles for in vivo gene transfer. These vectors are quickly
destroyed by complement and have a short half-life in the organism. However, the application
of these vectors in cultured cells is an efficient and easy process. In addition, the integration
of the provirus ensures that the viral sequence will be passed on to daughter cells after division
of the host cell. These characteristics give retroviral vectors an advantage in treatments that
require long term expression of the transgene and where ex vivo cell manipulation is antici‐
pated, such as the case for treating SCID [13].
Retroviruses have regulatory elements, called long terminal repeats (LTRs) that act as a
promoter do drive the expression of viral genes. In recombinant vectors, the LTR can be
employed to drive expression of the therapeutic gene, a common practice with gammaretro‐
viral vectors (Figure 3). For safety reasons, the LTR can be inactivated (by deletion of the
enhancer sequences contained in the U3 region). Such ‘self-inactivating’ or ‘SIN’ vectors
require the use of an internal heterologous promoter to drive transgene expression (Figure
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3). This practice has long been employed in lentiviral vectors since it offers an additional
assurance that recombination between transfer and packaging vectors will not produce a
viable, replication competent progeny. An additional safety feature offered by SIN vectors is
the decreased chance that the LTR will act as a promoter of host gene expression. The juxta‐
position of the LTR and a host gene can result in the unwanted expression of that gene
(insertional mutagenesis). In the case of a proto-oncogene, the cell would then be at risk of
transformation. This is essentially the cause of the cases of leukemia seen in the SCID-X1 trials.
Currently, SIN retroviral vectors are favored since they are less likely to activate the expression
of cellular genes, especially if the internal promoter does not contain a strong enhancer (for
example, the EF1a promoter) [13, 14].
Figure 3. Schematic representation of the retroviral vectors and production. The gene of interest in cloned in a plas‐
mid (transfer vector) that contains the retroviral regulatory elements (LTR, long terminal repeats) as well as elements
to regulate the expression of the transgene. The transfer vector is co-transfected along with the necessary packaging
vectors in 293T cells (an easily transfected cell line derived from HEK293) where viral progeny are formed, bud from
the cell surface and accumulate in the culture medium (supernatant). For gammaretrovirus, the transfer vector (A) can
be transfected along with a single packaging vector (B) or, alternatively, with two additional vectors (C) that result in a
pseudotyped virus progeny. For lentivirus, third generation transfer and packaging vectors are shown (D) which are all
co-transfected in 293T to form virus progeny. Note that the lentiviral vectors do not contain any viral genes associated
with HIV pathogenesis. CMV, cytomegalovirus promoter; SV40, simian virus 40 promoter; NeoR, neomycin resistance
gene; Gag, group specific antigen (structural proteins); Pro, pol, viral enzymes integrase, protease and reverse tran‐
scriptase; pA, polyadenylation signal; VSVg, envelope glycoprotein of vesicular stomatitis virus; R, U5, repeat and U5
regions of the LTR; ΔU3, U3 region deleted from the LTR; SD, SA, splice donor, splice acceptor; Ψ, Psi encapsidation
signal; RRE, rev-responsive element; Rev, lentiviral rev protein that regulates splicing events of the viral RNA; cPPT, cen‐
tral polypurine tract which facilitates nuclear importation of the lentiviral genome; WPRE, woodchuck hepatitis virus
post-transcritptional regulatory element which facilitates nuclear export of the viral transcripts; EF1a, elongation fac‐
tor 1-alpha promoter which is often employed in retroviral vectors.
Lentiviral vectors are thought to be safer than gammaretroviruses due mainly to their proviral
integration preferences. Though neither has a specific integration site, gammaretroviruses
have a greater tendency to integrate near the transcriptional start sites of cellular genes than
lentivirus [15]. In other words, gammaretroviruses are thought to be more apt to promote
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unwanted expression of cellular genes. In the case of SCID-X1, SIN lentiviral vectors present
one of the best currently available technologies for the safe transfer of the therapeutic gene [9].
Retroviral vectors play an important role in cancer gene therapy approaches. As will be
described in detail, retroviral vectors are frequently used to modify components of the immune
system in order to promote an anti-tumor immune response. Though the use of gammaretro‐
viral vectors for this purpose has not met with any unwanted side effects, lentiviral vectors
are gaining popularity due to their efficiency and safety.
5. Vectors: Adenovirus
Recombinant adenoviral vectors are the vehicle of choice for in situ gene therapy of solid tu‐
mors (Table 2). Such vectors can be produced at high concentration (1012 particles/mL) and
are quite well equipped to mediate gene transfer in vivo. The genome of the adenoviral vec‐
tor remains episomal, thus the issues related to provirus integration (discussed above) are
rendered moot. However, adenoviral vectors are known for provoking an anti-viral immune
response. In the case of cancer gene therapy, the anti-viral immune response has not been
associated with serious adverse effects and may even provide a benefit of attracting the im‐
mune response to the tumor site. The episomal viral genome and anti-viral immune re‐
sponse limit the duration of vector function, thus making adenoviral vectors inappropriate
for the long term treatment of chronic diseases, such as hemophilia or SCID. Yet, the short-
lived presence of transduced cells is compatible with cancer gene therapy since the goal is to
express a factor that results in the elimination of the tumor cell, a process that does not re‐
quire long term expression of the transgene [16-19].
The wild-type serotype 5 adenovirus (Ad5) has a linear, dsDNA genome of approximately
36 kb surrounded by a protein capsid from which fiber proteins project (Figure 1). The fiber
protein mediates interaction with the Ad5 cognate receptor, CAR (Coxsackie Adenovirus
Receptor) (Figure 4). The penton base then interacts with αv integrins and the virus particle
is then internalized, travels to the nucleus via microtubules and, finally, the viral DNA is de‐
posited in the nucleus, a process that is independent of cell division. The viral genome re‐
mains episomal while viral transcripts are expressed and progeny are formed. In this case,
virus progeny accumulate within the cell eventually resulting in cell lysis and the liberation
of viral progeny. Adenoviral replication requires the activity of the viral E1a and E1b pro‐
teins which inactivate Rb and p53, respectively, and are involved in transport of viral tran‐
scripts and promote the expression of other viral genes [16-19].
In the laboratory, recombinant adenoviral vectors (Ad) are manipulated in the form of plas‐
mids (Figure 5). The transfer vector encodes the gene of interest and the viral vector encodes
the remainder of the viral sequence, except that E1a and E1b are deleted. Since the viral vector
is quite cumbersome (approximately 40 kb), traditional cloning methods are inefficient for in‐
serting the gene of interest. Alternatively, recombination between the transfer vector and viral
vector may be performed or the use of rare restriction sites may be employed, either method re‐
sulting in a new plasmid that contains both the gene of interest and the viral sequence.
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Figure 4. Schematic representation of the adenoviral life cycle. For serotype 5 adenovirus, the knob portion of the
fiber protein mediates interaction with the cellular receptor, CAR (Coxsackie Adenovirus Receptor). In a second step of
viral/cellular interaction, the penton base then binds with the integrin αvβ3. The virus is then internalized, partially dis‐
assembled and the capsid is carried to the nucleus my the microtubule network. The viral genome is deposited in the
nucleus where expression of the viral genes results in the formation of progeny which accumulate intracellularly,
eventually causing lysis and release of progeny.
Figure 5. Schematic representation of recombinant adenoviral vectors and production. (A) The gene of interest is in‐
serted in the small transfer vector which is then recombined with the rest of the viral genome. However, the recombi‐
nant genome is devoid of the E1a and E1b genes (thus limiting viral replication). (B) The resulting plasmid is then
transfected in HEK293 cells (which harbor the E1a and E1b genes), thus initiating the production of virus. (C) The ini‐
tial production is then used to infect fresh HEK293 cells, thus amplifying virus production. (D) Photomicrograph of
HEK293 cells suffering from the cytopathic effect induced by the replicating adenoviral vector which, in this case, enc‐
odes eGFP (enhanced green fluorescent protein). (E) Step and (F) continuous CsCl gradient purification of the virus
progeny (indicated by the arrows). (G) Cells transduced with the now purified virus progeny is evidenced by their ex‐
pression of eGFP.
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The new plasmid containing the gene of interest as well as the viral components is transfected
into an appropriate cell line in order to initiate the production of virus particles. Since the
plasmid is devoid of E1a and E1b, the vector does not provide sufficient information to promote
virus production. Instead, the cell line used, HEK293, already contains the E1 genes and
provides expression of E1a and E1b in trans. In this way, only when the plasmid is introduced
in HEK293 cells is virus production initiated. The progeny viruses formed are also deficient
for replication since they too lack the E1 gene. However, the progeny virus can then be used
to infect fresh HEK293 cells (a process that is much more efficient than transfection) and
additional virus progeny will be formed. This ‘amplification’ of virus is repeated until a
suitable volume of viral lysate has been generated. This, in turn, must be purified (at lab scale
by CsCl gradient centrifugation, at industrial scale by filtration and chromatography) to rid
the virus particles of cellular debris [16-19].
Even after purification, the virus progeny will contain a mixture of viable, infectious particles
and defective, incomplete virus capsids. When using the virus to transduce a target cell, only
the viable particle will result in transgene expression. However, the defective particles
contribute to the load of antigens that the cell/organism receives and, with increased antigen,
comes an increased chance of provoking an immune response, much as was seen in the case
of Jessie Gelsinger. For this reason, care should be given to distinguish between the total viral
load and infectious particles used [20]. Generally, total virus load is expressed as VP/mL (virus
particles per milliliter) and infectious virus as IU/mL or PFU/mL (infectious units/mL or plaque
forming units/mL). Even in high quality preparations, VP/mL will be 10 to 25 times greater
than IU/mL.
Adenoviral  vectors  have  evolved  since  their  initial  use  was  described.  First  generation
vectors have deletions in the E1 and E3 genes, thus limiting replication and eliminating a
non-essential viral gene. In an attempt to reduce the anti-viral immune response, second
generation  vectors  with  deletion  in  the  E4  region  (gene  non-critical  to  viral  replication,
but which contributes to immune activation) were developed. The third generation of ad‐
enoviral vectors is devoid of any gene encoding an adenoviral protein. Though this com‐
plicates  the  strategy  for  virus  production,  it  does  yield  virus  that  are  much  less
immunogenic and provide more prolonged expression of the transgene. Even with these
improvements, most cancer gene therapy protocols involving adenovirus use first genera‐
tion vectors [16, 17].
Expression of the transgene encoded by the adenoviral vector requires the use of an internal
heterologous promoter. This provides the opportunity for transcriptional targeting or a strong,
constitutively active promoter, such as CMV, may be used. In first generation adenoviral
vectors, a total of 7 kb of sequence may be inserted. Especially for cancer gene therapy, this is
quite adequate for a promoter, transgene (or two) and polyadenylation signal.
As mentioned above, CAR is the cellular protein that mediates the interaction with Ad5 (Figure
4). In the absence of CAR, Ad5 transduction is quite inefficient. Though many cell types express
CAR, some do not, including certain types of cancer (melanoma) and some cancer stem cells.
In this case, engineering of the virus may be required so that interaction with CAR is no longer
necessary for successful transduction. One such approach involves the insertion of the RGD
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tripeptide in the H1 loop of the knob protein. In this case, the principal receptor is now αv
integrins which are widely expressed. By similar methods, the knob can also be adapted so
that it interacts with specific cellular receptors of interest. That is to say, transductional
targeting is achieved by altering the knob protein [17, 21].
If an adenoviral vector can be targeted at the levels of transcription and transduction, then it
becomes tempting to apply the virus systemically with the expectation that it will have
specificity for the target cell, such as the tumor. Unfortunately, other components of the virus,
such as the fiber and the capsid, mediate interactions with heparin sulfate and factor X, both
of which are highly abundant in the liver. In other words, attempts to apply the virus system‐
ically are thwarted by viral sequestration in the liver. Even worse, the virus tends to transduce
Kupfer cells (liver macrophages) that, in turn, present viral antigens to the immune system
and induce an immune response. This implies that even the treatment of hepatocarcinomas
by systemic administration of adenovirus will be undermined by transduction of Kupfer cells.
Extensive engineering of the vector is required in order to prevent transduction of liver cells
while directing transduction to the correct target [17, 22]. Though a few laboratory studies
point to the viability of this approach, for now it remains quite problematic. Successful
application of adenoviral vectors is typically performed by in situ injection of the virus into
the tumor mass.
6. Vectors: Oncolytic adenovirus
Up to this point we have described vectors that are deficient for replication. However, viral
replication can also be used to benefit the treatment of cancer. Such oncolytic or virotherapies
rely on the viral replication to cause lysis of the tumor cell. The resulting progeny can then
infect additional tumor cells and repeat the process, in theory, until all tumor cells have been
eliminated. Clearly, such an approach requires extensive engineering of the vector such that
replication is permitted only in the tumor cell, thus sparing normal cells [23].
An additional benefit to the oncolytic approach is that cell death does not depend on apoptosis.
A fundamental feature of tumor cells is their resistance to cell death even in response to signals
that would, in a normal cell, be fatal. Since oncolytic activity is not dependent on cellular genes,
there is a greatly reduced chance that the cell would develop resistance to the viral activity.
The same cannot be said for many pharmacologic approaches [23].
Several viruses, such as Herpes Simplex, Vaccinia and even retroviral vectors have been
developed into oncolytics. However, for simplicity, we will focus on conditionally replicating
adenoviruses (CRAds). The key to controlling CRAds lies in the E1 genes. As mentioned above,
adenoviral replication requires the function of the E1a and E1b proteins (encoded by the E1
genes). If E1a and/or E1b function is permitted only in tumor cells, then the virus will replicate
only in tumor cells. One approach uses a tumor-specific promoter to drive expression of the
E1 gene. Promoters such as hTert, E2F1 and survivin are much more active in tumor cells than
in differentiated adult tissues. The use of one of these promoters to drive E1 gene expression
creates a degree of tumor specificity [23].
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Another approach involves the use of a mutant version of the E1a gene. Adenoviral replication
is not supported in the presence of wild type Rb and, for this reason, E1a has evolved to
interrupt Rb activity. Since Rb is typically inactivated in tumor cells, E1a is no longer required
to provide this function. Deletion of the 24 amino acids from E1a which mediate its interaction
with Rb results in an altered E1a protein that no longer blocks Rb function. In a normal cell,
the persistence of Rb function blocks viral replication. In a tumor cell, the typical loss of Rb
activity creates a condition where viral replication is supported. CRAds that combine trans‐
ductionoal and transcriptional targeting as well as the E1a deletion mutant have been created
and tested with promising results [23-25].
A classic example of an oncolytic adenovirus was originally known as Onyx-015. In this vector,
the E1b gene was mutated with the intention of permitting viral replication in p53-deficient
cells, but normal cells, with wild-type p53, should not allow viral replication. This vector has
been widely studied and even approved for commercialization in China (Table 1). However,
it was later noted that the underlying mechanism that controls Onyx-015 replication is not
related to the p53 status, but instead to the RNA export functions of the E1b protein [26, 27].
In addition to the sophisticated engineering of the CRAds, some these vector also carry a
therapeutic gene. Such vectors are referred to as armed CRAds. For example, the expression
of GM-CSF or interferon-β together with the activity of the CRAd should promote an anti-
tumor immune response. Alternatively, the vector may be armed with additional death-
inducing factors, such as the thymidine kinase gene (TK) derived from herpes simplex virus.
In this case, the application of the prodrug ganciclovir induces cell killing and augments the
effect of the CRAd. Another approach involves the use of the TNF-related apoptosis-inducing
ligand (TRAIL) which, when cleaved into a soluble form, induces apoptosis in tumor, but not
normal, cells [24, 25, 28].
In all, oncolytic viruses can combine tumor specific activities in order to bring about cell death
independent of apoptosis, but can also be armed to induce apoptosis, immune activation and
interrupt cellular DNA replication.
7. Vectors: Non-viral
The typical  non-viral  vector  is  a  recombinant  plasmid,  though oligos,  siRNA and RNA
fall  into  this  category.  Recombinant  plasmids are  derived from their  wild-type counter‐
part,  a  small  circle  of  episomal  dsDNA  found  in  a  variety  of  bacteria.  In  the  lab,  we
need  only  maintain  regulatory  sequences  that  control  the  replication  of  the  plasmid  in
their  bacterial  host  as  well  as  an antibiotic  resistance gene that  facilitates  the manipula‐
tion and maintenance of the plasmid in the lab. The therapeutic gene of interest is then
inserted along with appropriate regulatory sequences (such as a promoter and polyade‐
nylation site). Once constructed, the production of the vector is performed using well es‐
tablished techniques involving large volumes of bacterial cultures and purification of the
plasmid by filtration and chromatography [29-31].
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Though the use of plasmid vectors is quite routine and performed in a great many research
labs on a daily basis, some considerations of vector design and delivery should be taken into
account. The vector itself should not contain extraneous sequences that are not part of the
treatment. That is to say, the vector delivered to the patient should not contain antibiotic
resistance genes or regulatory sequences of bacterial origin. Such sequences could provide
expression of unwanted peptides or even contain GC rich sequences, both known to provoke
immune responses. However, production of plasmids requires the presence of just such
regulatory sequences. To overcome this, the plasmids are often engineered such that once the
bacteria and the plasmids they contain have been expanded to the necessary volume, recom‐
bination can be induced such that the unwanted sequences are eliminated and only the small
circular DNA containing the gene of interest remains. It is this small circular DNA that is then
purified and delivered to the patient, free of non-essential sequences [31].
Plasmid delivery can be performed by direct injection of ‘naked’ DNA with or without physical
methods to promote transfection, such as the gene gun, electroporation or microbubbles.
Alternatively, the plasmid may be complexed with chemical compounds that facilitate its
passage across the cell membrane. Such complexes may include lipids, polyethylene glycol,
polyethyleneimine or other compounds can both secure the DNA molecules as well as mediate
cellular uptake. Such approaches are often referred to as ‘nanotechnology’ since these virus-
sized particles can be engineered to achieve high levels of transfection and can even include
targeting strategies (such as described for transductional targeting) [30, 32-35].
While non-viral gene transfer may be relatively efficient, simple and safe, the episomal nature
of the plasmid and limited half-lives of oligos and mRNA often result in short lived expression
of the therapeutic gene. As the cell divides or as the transfected material degrades, the
therapeutic gene is lost. Such an approach may be inappropriate for the treatment of chronic
illnesses, such as immune deficiencies or metabolic disorders. However, non-viral gene
transfer is an interesting option when limited transgene expression is sufficient or desirable,
such as for the induction of angiogenesis in ischemic tissues or, in the case of cancer, induction
of cell death and/or a tumor-specific immune response.
Recently, a new approach was described for non-viral gene transfer to the skin. This new
technology involves the use of an array of very small needles that breakdown over time and
has been termed dissolvable protrusion array device (PAD) [36, 37]. For this, an array of pins
is dipped in a polyvinyl alcohol polymer solution and slowly raised while drying; essentially
creating hollow core stalagmites that can be filled with a solution of nucleic acid, such as
siRNA. The array of microneedles can then be applied to the skin, penetrating the stratum
corneum barrier and depositing the material where it dissolves and locally releases the
therapeutic payload. As a demonstration of this technology, human skin xenografts were
treated with PAD loaded with an siRNA againt CD44 and significant reduction in target gene
expression was observed [36, 37]. In theory, the PAD can be loaded with more than one
therapeutic sequence or even with chemotherapeutic drugs, so it is easy to imagine the
administration of genetic and pharmacologic therapies directly to the cutaneous tumor mass.
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8. Strategies of melanoma gene therapy
Melanoma has played an important part in the history and development of gene therapy. The
first clinical trial to use gene therapy to treat cancer was performed at the US National Institute
of Health (NIH) Clinical Center in February of 1991, lead by Steven Rosenberg of the National
Cancer Institute (NCI). When the results were published, they affirmed that “ attempts at gene
therapy for cancer are underway ….” [38].
In fact, the milestone study was based on work initiated several years before. Since 1986,
Rosenberg had increasing success in treating intractable melanomas with TIL cells (tumor
infiltrating lymphocytes) that are surgically removed from a patient’s cancer and cultured for
4 to 6 weeks in the laboratory along with interlekin-2 (IL-2), a growth factor that stimulates
the immune system, and then the cells are re-infused into the patient. The TILs have a selective
affinity for the tumors from which they came, so the TIL-IL2 cells can infiltrate the primary
tumors and their metastases [39]. However, as with many new therapies, TIL-IL2 only works
a fraction of the time. The question was why? Are the cells reaching their target? A gene transfer
experiment was proposed in an attempt to answer that.
The experimental strategy was relatively simple. The first step was to genetically modify
human  TILs  through  the  introduction  of  a  foreign  marker  gene  in  the  laboratory  (ex
vivo).  The  gene  for  a  bacterial  enzyme  encoding  neomycin  phosphotransferase  (neoR),
which transmits resistance to the antibiotic G418,  was chosen. Using a gammaretrovirus
to  deliver  the  neo  gene,  a  population  of  TILs  were  marked  ex  vivo.  Rosenberg,  Blaese
and Anderson succeeded in getting more than 5% of TILs to take up the neo gene. After
administration, these modified TILs can be easy identified in patients’ pheripheral blood
and tumor biopsies. In 1989, the first of ten patients with end-stage melanoma was treat‐
ed  with  infusion  of  TILs  transduced  with  gammretrovirus  and,  by  following  the  neo-
marker,  the  research  team  could  follow  the  TILs.  This  initial  study  was  designed  to
determine the long-term traffic patterns and distribution of TILs in the body. It  was not
expected  to  offer  any  medical  benefit,  yet  this  clinical  experiment  demonstrated  that
gammaretrovirus-mediated transduction could be used to safely modify human lympho‐
cytes  which  were  subsequently  administered  to  the  patient.  This  trial  led  to  additional
gene transfer protocols utilizing therapeutic genes with potential for clinical benefit [40].
This and other early gene marking studies suggested that recombinant gene transfer could be
achieved in a selected subpopulation of cells. These pioneering trials also helped address
important regulatory concerns and stimulated research into delivery vehicles with applica‐
tions for inherited and acquired diseases. Interestingly, in parallel, M. Blaese and F. Anderson
used a similar approach where the gene for adenosine deaminase was transferred by gam‐
maretrovirus into lymphocytes of children with severe combined immunodeficiency disease
and is regarded as the first therapeutic gene therapy trial, as mentioned above [7].
Since Rosenberg knew that TILs localize at tumor sites and that TILs can be safely modified
with gammaretrovirus, he then attemped to introduce TNF (tumor necrosis factor-alpha) into
TILs and use these genetically modified cells as vehicles to deliver TNF, a potent antitumor
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protein, directly into the tumor. This trial represents the first time a candidate therapeutic gene
was introduced into human cells with the goal of treating cancer [41]. Three late-stage
melanoma patients were treated with unselected TILs that had been transduced with the TNF
gammaretrovirus, but the subsequent seven patients received modified TILs that were selected
for G418 resistance in order to increase the fraction of tranduced cells present in the TIL
cultures. The modified TILs were expected to accumulate at the tumor sites and produce local
concentrations of TNF high enough to mediate tumor death, yet without exposing the patient
to high systemic doses of TNF. The treatment was well tolerated and, as often seen in phase I
safety trials, clinical benefit was not profound [38]. However, this trial paved the way for future
cancer gene therapy efforts.
To date, some 1186 cancer gene therapy trials have been cited, representing approximate‐
ly  65%  of  all  gene  therapy  clinical  protocols  (http://www.wiley.com/legacy/wileychi/
genmed/clinical/).  A great  many approaches have been attempted with the fundamental
goal of eliminating the tumor cells by direct induction of cell death or by induction of an
anti-tumor immune response. Specifically in the case of melanoma, some 161 trials have
been cited  (Figure  6).  In  fact,  melanoma is  the  most  frequent  indication  seen  in  cancer
gene  therapy  trials,  even  more  than  prostate,  lung  or  breast.  Among  these  melanoma
gene therapy trials,  7  phase III  protocols  have been cited.  These include transfer  of  the
B7.1 gene (5 trials) and GM-CSF (2 trial).
Figure 6. Progress in clinical trials of melanoma gene therapy. (A) Distribution of more frequent indications for cancer
gene therapy. (B) Distribution of clinical trials of melanoma gene therapy by phase. Data extracted from Journal of
Gene Medicine Clinical Trial Database (current as of June 2012).
These clinical trials highlight the variety of approaches that have been attempted (Figure 7).
These include strategies of viral gene transfer (62% of trials), where adenovirus and gammar‐
etrovirus are the most used. Non-viral vectors (38% of trials) have been used as naked DNA
or in conjunction with physical and chemical means of improving their efficiency. Strategies
have included the transfer of seven principal gene families, including interleukins, tumor
associated antigens, suicide genes and genes for the modulation of the immune response (GM-
CSF, B7.1 and type I interferon). In the following discussion we present some illustrative
examples from pre-clinical to phase III trials.
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Figure 7. Strategies of melanoma gene therapy tested in the clinic. (A) Frequency of vector usage. (B) Therapeutic
gene type used. Data extracted from Journal of Gene Medicine Clinical Trial Database (current as of June 2012).
9. Suicide genes
A classic cancer gene therapy approach involves the transfer of a ‘suicide gene’ or ‘gene
directed enzyme prodrug therapy’. In this scenario, an enzyme is introduced in the target cell
by gene transfer. This enzyme alone does not have an effect on the cell, but when an appropriate
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prodrug is administered, the enzyme converts the innocuous prodrug into an active, death
inducing compound. Two of the better known examples are the thymidine kinase gene derived
from herpes simplex virus (HSV-TK) which promotes phosphorylation of the prodrug
ganciclovir and the bacterial cytosine deaminase (CD) gene which converts the prodrug 5-
fluorocytidine (5FC) into the chemotherapeutic agent 5-fluorouracil (5FU). In both cases, the
compound produced by the enzyme/prodrug interaction blocks DNA replication and, as a
result, induces cell death. The advantages of suicide gene therapy include very limited reaction
to the enzyme or prodrug in isolation, yet their combination results in a localized concentration
of an anti-neoplastic agent. Since DNA replication is a prerequisite for the action of the
modified prodrug, this approach has specificity for dividing cells and spares post-mitotic cells
even in the case that they should be transduced. Suicide gene therapy is aided by the ‘by‐
stander’ effect where the modified prodrug may be passed from a transduced cell to a non-
transduced neighbor, killing it only if it is actively dividing. In addition, at least in the case of
HSV-TK/ganciclovir, a significant tumor-specific immune response may be elicited, thus
amplifying the effects of the gene therapy even further [42].
Specifically in the case of melanoma, a few examples of clinical application of suicide genes
have been reported. For example, a phase I/II study utilized a gammaretroviral vector for the
transfer of the HSV-tk gene to melanoma patients. However, these authors actually implanted
cells that were actively producing the vector in the patients. In this way, the tumor cells would
receive a constant supply of virus until administration of the prodrug which would then bring
about the death of both the tumor cells and the virus producing cells. These treatments were
associated with well tolerated inflammatory skin reactions and moderate fever. During
ganciclovir treatment, the tumors did show signs of shrinkage, but increased in size upon drug
withdrawal. These results are quite encouraging given that the treatment was well tolerated
and showed signs of clinical benefit, at least during the prodrug treatment [43].
In a separate trial, 13 melanoma patients were treated with gammaretrovirus by direct injection
of the virus particles into the tumor mass followed by ganciclovir administration. The gene
transfer protocol was well tolerated with only one patient showing grade III pain at the
injection site. The treatment with the prodrug was associated with some side effects, including
dyspnea, pain and poor appetite. However, no response was detected when comparing
injected and non-injected tumors. Though the desired result was no observed, the gene therapy
procedure was well tolerated [44].
Laboratory assays using CD have yielded some promising results and also exemplify inter‐
esting technologies. For example, Kucerova et al [45] have used mesenchymal stem cells to
infiltrate melanoma tumors in a mouse model. In this case, the mesenchymal stem cells offer
the advantage of migration to and within the tumor mass, an inherent property of these cells.
The human fat-derived mesenchymal cells were transduced with a gammaretrovirus encoding
the CD gene and delivered i.v. or i.p. in nude mice bearing a tumor derived from a human
melanoma cell line (A375). Significant inhibition of tumor progression was seen with the i.v.
injection of the CD-expressing mesenchymal cells plus 5FC treatment [45].
In another example involving CD/5FC, an adenoviral vector was targeted to tumor vascular
endothelial cells at both the transductional and transcriptional levels. For this, the adenoviral
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vector displayed the RGD tripeptide in the H1 loop of a mutated fiber knob protein (so that
transduction depends on αvβ3 integrins instead of CAR) and also used the endothelial cell-
specific Tie2 receptor promoter to drive expression of the CD gene. B16 tumors were estab‐
lished in nude mice and the modified adenovirus was administered i.v., but only after pre-
treatment with hetastarch, a reagent that effectively blocks hepatic uptake of adenovirus. The
authors report that only endothelials, pericytes and tumor monocytes were transduced, but
not the tumor cells themselves. Administration of 5FC resulted in significant inhibition of
tumor progression [46].
10. Adoptive cell transfer
One of the most promising frontiers of cancer therapy is the use of adoptive cell transfer (ACT).
Especially in the case of metastatic melanoma, where few options exist, ACT may overcome
some of the limitations seen with even the most promising treatments (including high-dose
IL-2 and anti-CTLA-4). In addition, a naturally occurring, tumor specific T cell response is seen
in a large percentage of melanoma patients, suggesting that these tumors are immunogenic
and that T cells can be made to recognize them. ACT utilizes the patients’ own T cells where
they are activated ex vivo, expanded, and returned to the patient to carry out tumor-specific
cytolysis. Since gene transfer is the theme of this chapter, we will focus on approaches that
involve genetic modification of either the T cells themselves or of the dendritic cells (DC) used
to activate them. At its core, ACT is used to generate T cells that are tumor reactive, though
several approaches have been described [47, 48].
Tumor infiltrating lymphocytes (TILs) can be isolated from melanoma biopsies and the T cells
expanded ex vivo. This approach, which does not involve genetic modification, relies on two
critical factors, the ability to isolate T cells and expanding them to clinically significant
numbers. Over time, alternatives to this approach have been explored, such as preconditioning
by lymphodepletion, the use of young TILs (cells that have not undergone extensive expansion
ex vivo) or enrichment for CD8+ TILs. Isolation of T cell clones from TILs that are specific for
melanoma associated antigens (such as MART1/MelanA, NY-ESO-1 or gp100) can also be
performed, but this process requires 3 to 5 months and the clinical outcome (50% objective
response) does not surpass that seen with polyclonal TILs [47, 48].
The above argument points to considerable success with ACT, however there is room for
improvement, especially with respect to tumor regression. Genetic modification of T cells as
a form of ACT has been developed and tested clinically. For example, the T cells may be
transduced with a retrovirus that provides expression of a cytokine, such as IL-2, IL-12 or IL-15
or may be modified to resist the effects of immunoregulatory factors. The aim here is to
preserve the function of the ACT, but does not necessarily assist in tumor reactivity of the T
cells. Thus far, IL-12 and IL-15 expressing cells are still being tested, while IL-2 expressing cells
did not show any advantage over non-modified ACT [47-50].
Since the role of the T cell receptor (TCR) is to mediate, in part, the recognition of and response
to specific antigens, the patients’ T cells may be modified by the introduction of a recombinant
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TCR with specificity for a tumor associated antigen. This is a time consuming process and the
clinical response rate is less than ideal, though this approach is often seen as an alternative for
those patients that failed to provide TILs from biopsies. In the ground-breaking work of
Morgan et al, peripheral blood lymphocytes from melanoma patients were transduced with a
gammaretrovirus encoding the alpha and beta chains of the MART-1-specific TCR. The
lymphodelpeted patients received an infusion of the genetically modified, autologous cells.
The persistence of these cells was variable and related to experimental conditions of each
cohort, but modified cells found even after 90 days. Two (out of 15) patients with progressive
metastatic melanoma showed full clinical regression with this treatment [51]. In a later trial
conducted by this group, they used improved versions of the TCR and observed a response
rate of 30% [52]. Though the response rate was low, these studies show the feasibility of this
approach and the importance of fine tuning the TCR.
In a related approach, T cells are modified to express a chimeric antigen receptor (CAR). CARs
are engineered molecules that consist of an antigen-recognizing domain derived from an
antibody (single-chain variable fragment) fused to a component of the TCR complex (CD3 zeta
chain) and, sometimes, also fused to a costimulatory molecule (such as CD28) [47, 48]. This
arrangement assures that antigen recognition is sufficient to activate T cell cytolytic function,
an interaction that is not HLA restricted and requires only low levels of antigen, thus stream‐
lining and amplifying the T cell response. The lack of HLA restriction implies that the CAR
modified T cells need not be autologous and a supply of cells may be generated and maintained
at the ready.
Treatment of melanoma with CAR-modified T cells has been performed only in preclinical
models, but these show promising results. For example, a CAR specific for ganglioside GD2
was developed in the Brenner laboratory, inserted in a gammaretroviral vector and used to
modify T cells. When these cells were exposed to melanoma cells expressing GD2, cytokines
were released and melanoma cells were eliminated both in vitro and in vivo [53]. In a similar
fashion, the Rosenberg and Morgan group has developed a high molecular weight melanoma
associated antigen (HMW-MAA or CSPG4)-specific CAR. Both CD4 and CD8 T cells express‐
ing this recombinant receptor were reactive and induced target cell cytolysis in an HLA-
independent manner [54].
Clinical trials with CAR-modified T cells have been performed for other tumor types, in‐
cluding ovarian cancer, neuroblastoma, leukemia and lymphoma and some clinical bene‐
fit  has  been  reported  [47,  48].  Unfortunately,  a  patient  being  treated  with  ERBB2-
targeted,  CAR-modified  T  cells  suffered  an  adverse  reaction  and died  when these  cells
lodged in the lung due to low level expression of ERBB2 and initiated a cytokine storm
[55]. In a separate trial, a patient treated with CD19-targeted cells also succumbed due, it
is believed, to a T cell response [56]. These unanticipated events should not detract from
the potential of CAR-modified T cells. Clearly, continued study of the CAR design and T
cell response is required and, no doubt, is forthcoming. Nor should this event reflect on
the field of gene therapy since safety issues related to the vector itself were not involved
in the function of the CAR and subsequent cellular responses.
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11. Vaccines
Since melanoma is well known to be an immunogenic tumor, there have been a great many
efforts to develop vaccines that induce an anti-melanoma response. Many approaches using
peptides, whole proteins, whole cell lysates delivered directly to the patient have been
attempted. Also, the introduction of GM-CSF in melanoma cells provides a vaccine that
promotes the immune response. Alternatively, dendritic cells themselves may be introduced
in the patient, a process that relies on the availability of such cells as well as their ability to
recruit and activate T cells in the cancer patient. Currently, much emphasis has been given to
the target specific approach of blocking CTLA-4 or PD1 with monoclonal antibodies, thus
promoting T cell function, for the treatment of melanoma [57]. Future hopes involve the
combination of these vaccine and targeted modalities.
GM-CSF acts by recruiting and promoting the maturation of DCs, a process that is  cru‐
cial to mounting an effective immune response. Many studies have explored the genetic
modification of tumor cells with gammaretroviral vectors expressing GM-CSF, irradiation
of these cells and subsequent use of these cells as a tumor vaccine. Soiffer et al  [58,  59]
observed that  metastatic  lesions  in  11  of  16  treated patients  had a  dense  infiltrate  of  T
cells  and  extensive  tumor  destruction,  a  phenomenon  not  seen  in  the  absence  of  this
treatment.  Vaccination  sites  showed  adverse  effects,  such  as  erythema  and  induration
and occasional hemorrhaging, otherwise the treatment was well tolerated [58].  In a later
trial, this group used adenovirus instead of the gammaretroviral vector for GM-CSF gene
transfer to patient-derived metastatic melanoma cells,  followed by irradiation and vacci‐
nation. The vaccine was successfully produced for 34 of 35 patients and toxicities includ‐
ed  only  grade  1  to  2  local  skin  reactions.  Again,  infiltration  and  necrosis  of  metastatic
sites  was  observed  (10  of  16  patients).  After  36  months  of  follow-up,  29%  of  patients
were still alive, four of whom showed no evidence of disease [59].
Though the GM-CSF secreting cells provided some measure of improvement, the successful
vaccine requires an abundance of functional T cells to carry out cytolysis. One factor that blocks
T cell function in many cancer patients is the CTLA-4 gene. By blocking CTLA-4 function, T
cell activity is liberated. Ipilumimab, a monoclonal antibody that binds to and blocks CTLA-4
function was recently approved by the FDA for the treatment of late stage melanoma [57].
Studies by the Dranoff group applied ipilumimab in melanoma patients that had previously
been treated with the GM-CSF secreting cellular vaccine [60, 61]. The observations included
only low grade inflammatory toxicities, though high level ipilumimab treatment is known to
cause high grade toxicity in 15 to 25% of melanoma patients. Though not designed to reveal
clinical benefit, evidence of tumor shrinkage was observed in some patients. Since ipilumimab
also increases the number of Tregs, proper T cell function may require a specific balance
between effector and regulatory cells. A future direction may be to combine the vaccine,
ipilumimab and an inhibitor of Tregs [60].
As an alternative,  DCs can be modified ex vivo  with antigens or a vector or mRNA en‐
coding tumor associated antigens. These professional antigen presenting cells can then be
introduced  in  the  patient  as  an  immunotherapy.  For  example,  the  work  of  Steele  et  al
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[62]  describes  the  transfection of  a  plasmid encoding both melan-A and gp100 into  DC
derived from the patients’ own PBMCs followed by delivery of these gene-modified cells
in the stage IV melanoma patients (n=27). The number of rounds of vaccination was vari‐
able, between 1 and 14, though 15 patients received 4 rounds of treatment. In all, partial
response  or  stable  disease  was  seen  in  seven  patients  and  treatment-related  adverse
events  were  quite  mild  (flu-like  symptoms  or  mild  erythema  at  the  injection  site).  As
with  many  early  phase  trials,  these  results  show that  the  treatment  was  well  tolerated
and that a positive response was seen in a few patients [62].
12. Oncolytic viruses (virotherapy)
As described above, oncolytic vectors use the lytic virus life cycle in order to destroy cancer
cells. These vectors are engineered so that replication can occur only in tumor cells and, in
some cases, are armed with a gene to aide in tumor cell killing. The engineering may include
transductional and transcriptional targeting, alteration of viral replication genes and the
insertion of a functional transgene.
Some interesting examples of conditionally replicating adenoviruses for virotherapy of mouse
models of melanoma have been reported. For example, the group of Albert Deisseroth has
developed an oncolytic vector where expression of E1a is controlled by the tyrosinase pro‐
moter. Tyrosinase, a melanoma associated antigen, is an important factor in melanogenesis
and may even have additional regulatory functions [63]. In this way, E1a expression from the
vector should be melanoma-specific. In addition, the vector was modified with the insertion
of the RGD tripeptide in the H1 loop of the fiber knob protein, much as was discussed above.
This vector showed increased infectivity in melanoma cells and suppressed growth of
xenograft tumor models [64].
In an alternative approach, an oncolytic adenovirus was developed where the SPARC (secreted
protein acidic and rich in cysteines) promoter was used to drive expression of E1a. In this case,
the SPARC promoter should support viral replication not only in the tumor cells, but also in
tumor associated stromal cells. Though this approach was beneficial for a model of pancreatic
carcinoma, the authors observed that the stromal cells in the melanoma model actually
hampered virus performance [65]. This study is interesting since it points out the importance
and complexity of the tumor microenvironment on the gene therapy approach.
In a final pre-clinical example, an oncolytic adenovirus was developed which was armed with
IL-24 (MDA-7, melanoma differentiation-associated gene-7) as well as arrestin. IL-24, a
secreted protein, inhibits melanoma by autocrine and paracrine effects, including inhibition
of angiogenesis, immune stimulation and radiosensitization. Arrestin also inhibits angiogen‐
esis and tumor growth. With this doubly-armed oncolytic vector, it was shown that melanoma
cells were significantly inhibited both in vitro and in vivo, the latter being associated with
reduced angiogenesis and increased apoptosis [66].
Oncolytic vectors have also been tested clinically. We start by describing a second generation
HSV (herpes simplex virus) oncolytic that was developed by deleting not only the ICP34.5
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gene (typical of first generation vectors), but also the ICP47 gene which impedes antigen
expression. In addition, early expression of another viral factor, US11, promotes tumor-specific
virus replication. Finally, this vector was armed with GM-CSF (which promotes dendritic cell
maturation and, thus, anti-tumor immune response) and termed OncoVEXGM-CSF. In a phase I
dose escalation trial, viral treatments were generally well tolerated, but side effects were more
pronounced in patients who were HSV-seronegative before receiving treatment. Of the 26
evaluable patients, 3 showed stable diseaes (including 2 melanoma cases) and 6 showed
flattening of the treated tumors. Some notable aspects of this study were the relatively low
frequency of viral treatments, low viral dose and lack of chemotherapy required to induce a
response [67]. In phase II trials treating stage IIIc and IV melanoma, treatment with Onco‐
VexGM-CSF induced tumor specific (MART-1) CD8-positive T cells and reduced Tregs [68] and,
in a separate trial, resulted in a 26% response rate [69]. Currently, a phase III trial, ‘OPTIM:
OncovexGM-CSF pivotal trial in melanoma’ is underway [70].
The vaccinia virus, best known for its role in eradicating smallpox, has also been developed
into an oncolytic vector [71]. These vectors have a rapid lytic cycle, enter cells by membrane
fusion (and not a specific receptor) and the enveloped progeny are protected from immune
destruction, all factors that enable poxviruses to spread within the organism. Tumor specific
poxviruses rely on reduced type I intereferon response, increased rate of cell division,
decreased rate of apoptosis and immune evasion seen in tumor cells. In addition, the epidermal
growth factor receptor (EGFR)-Ras signaling pathway, which is typically active in tumor cells,
promotes poxvirus replication. Since tumor cells are naturally permissive for poxvirus
replication, viral transformation genes can be eliminated from the vector. In this way, the
vector will replicate only in tumor cells and leave normal cells unharmed. The oncolytic
poxvirus can also be armed, such as with the GM-CSF gene and with the bacterial β-galacto‐
sidase (LacZ) gene, serving as a marker for transduction as well as an antigen against which
antibodies can be generated and measured [71]. The JX-594 poxvirus possesses these features
and has been tested clinically.
In a proof of principle trial, 10 melanoma patients were enrolled and treated with no significant
side effects, mainly grade 1-2 flu-like symptoms. Post-treatment biopsies showed necrosis and/
or intense perivascular lymphocytic infiltration and radiographic tumor assessment, possible
in only 5 of the patients, all of which showed stable disease in the treated tumor and 3 patients
also showed stable disease at distant, non-treated sites [72].
The oncolytic vectors discussed above were delivered intratumorally. Intravenous delivery,
on the other hand, is quite challenging due to the multiple impediments that prevent the virus
from successfully reaching its target. However, JX-594 has been delivered i.v. and showed
clinical benefit. In this dose escalation study, 23 patients with solid tumors, including mela‐
noma, were treated and adverse effects were limited to grade 1-2 flu-like symptoms. Staining
for the β-galactosidase protein revealed the presence of the virus in tumor tissues. In addition,
anti-β-galactosidase antibodies were measured and revealed a dose-dependent relationship
with the viral load used to treat the patients. GM-CSF was detected in patient blood samples
only after treatment. Evidence of anti-tumor activity was noted, including >25% descrease in
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FDG-PET. This is study was the first to show dose-related delivery, replication and transgene
expression upon i.v. delivery [73].
13. B7.1
Tumor cells often escape detection by the immune system even when anti-tumor immune cells
are generated [74]. Among the many possible mechanisms for this phenomenon, metastatic
melanoma cells are quite often deficient for B7-1 and B7-2, factors that are essential for full T
cell activation. The lack of even one of these factors leads to T cell anergy, inactivation of the
T cell after encountering an antigen, essentially generating self-tolerance. In other words, the
lack of these factors actually teaches the T cells to ignore the melanoma. This implies that using
gene therapy to replace at least one of these missing factors should initiate tumor specific T
cell mediated cytolysis.
In 1993, Gary Nabel showed that a plasmid vector encoding HLA-B7 could be safely intro‐
duced into patients’ melanoma tumors by means of a liposome. One of the five patients showed
reduced tumor mass [75]. A subsequent trial by this group revealed T cell infiltration and TIL
reactivity was enhanced in treated patients. In addition, two patients showed local inhibition
of tumor growth [76]. The concept was then expanded upon by transfer of the β2-microglobulin
gene along with HLA-B7 in a single plasmid vector/liposome complex, a treatment now known
as Allovectin-7. In this way, Allovectin-7 provides an allogeneic MHC class I protein, essential
for antigen presentation and T cell activation [77].
Several phase II studies of Allovectin-7 have been completed. For example, Stopeck et al [78]
reported a regimen where 6 intratumoral injections of 10 μg of Allovectin-7 were performed
over a 9 week period. The treatment was well tolerated and regression of the injected lesion
was seen in 18% of patients, including a complete response and three partial responses [78].
A few years later, a phase II trial was described where 77 patients were treated with the same
Allovectin-7 regimen; 9.1% had complete or partial responses with 4.8 months median
duration of the response. Interestingly, this trial showed that the treatment was beneficial even
in lesions distant to the treatment site [79].
More recently, a phase II dose escalation study was reported [80]. In this study, 127 patients
received a total of 2 mg of plasmid DNA, some 10-times more than was used in the previous
trials. Complete response was seen in four patients, 11 achieved partial response and the
overall response rate was 11.8%. Stable disease was seen in 32 patients. Interestingly, the
duration of response was quite extensive, 13.8 months, and evidence of a systemic effect, such
as vitiligo and shrinkage of lesions distant to the treatment site, was seen in some patients. No
toxicities above grade 2 were noted, but adverse effects were consistent with the expected pro-
inflammatory response triggered by Allovectin-7 [80].
Variations of the HLA-B7 gene transfer strategy have also been explored. For example, the B7.1
cDNA has been inserted in a vaccinia virus. In this way, the virus introduces the HLA-B7 gene
to a large number of tumor cells and the vector itself may participate in the anti-tumor immune
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response. In a phase I trial involving 12 patients, intratumoral injection of the B7.1-armed
vaccinia virus, termed rV-B7.1, yielded no serious adverse effects, 2 patients with vitiligo,
partial objective response was seen in 1 patient and disease stabilization in 2. Patients devel‐
oped an anti-vaccinia antibody response and 5 of 6 patients showed increase in gp100-specific
T cells and 4 of 6 showed increase in MART-1-specific T cells. A patient with >59-month
survival post-treatment showed an increase in both of the T cell subsets [81].
The Kaufman group also established a vaccinia vector encoding not only B7.1, but also the
costimulatory molecules ICAM-1 and LFA-3 (intracellular adhesion molecule-1 and leukocyte
function-associated antigen-1, respectively). This new vector was termed rV-TRICOM. In a
phase I trial, side effects were limited to low grade reactions at the site of injection, yet there
was a 20.7% objective clinical response. One patient showed a complete response over a 22
month period. Due to the lack of HLA-A*0201 patients, anti-tumor immune responses were
not measured, yet anti-vaccinia responses were seen [82].
14. Interferon and interleukin gene transfer
Biochemotherapy, such as treatment with recombinant IL-2 or type I interferon, has shown
some degree of success. However, these approaches are hampered by the high doses needed
to overcome the short half-life of these proteins. Often, these high doses are come with
unwanted systemic toxicities [83, 84]. As an alternative approach, gene therapy may offer the
advantage of high concentrations of the therapeutic agent, but only localized to the tumor,
thus avoiding systemic toxicity.
Clinical trials with adenoviral vectors expressing IL-2 have been performed. For example,
Stewart et al [85] reported a lack of conventional clinical response, yet 24% of patients did show
incomplete local tumor regression. They also noted increased CD3 and CD8-positive TILs [85].
In another example, a phase I/II trial included 25 metastatic melanoma patients and 10 patients
with other solid tumors. Objective clinical responses, including 2 complete responses, were
seen in 5 of the melanoma patients who received the higher dosage of vector. Serum levels of
IL-2 were increased after treatment and were proportional to the vector dose used. Side effects
were limited to flu like symptoms [86].
IL-24 (or MDA-7, melanoma differentiation associated gene-7) has been extensively reviewed
and tested in a variety of pre-clinical models. IL-24 was isolated from human metastatic
melanoma cells previously treated by the combination of interferon-beta and mezerein, a
protein kinase C activator. This treatment induces a differentiated state that is associated with
the differential expression of a number of interesting genes, IL-24 among them. IL-24 is a novel
member of the IL-10 gene family and has been shown to depress growth and induce apoptosis
specifically in transformed, but not normal or immortalized, cells. In addition, IL-24 has been
associated with a potent bystander effect, implying that, in a gene therapy scenario, even non-
transduced tumor cells may be killed [87, 88].
To  the  best  of  our  knowledge,  two  phase  I  clinical  trial  has  been  reported  involving
IL-24 gene transfer  to  melanoma patients.  In  these  studies,  a  non-replicating adenoviral
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vector  encoding  IL-24,  termed  INGN  241,  induced  a  systemic  TH1  cytokine  response.
Objective responses, including complete response, was seen at higher vector dosages [89,
90]. Despite the melanoma origin of the IL-24 gene, it has been more extensively studied
for other tumor types [87].
Gene therapy of melanoma with interferons has not been extensively explored, even though
biochemotherapy with type I interferon is well known. One of the few examples includes
adenovirus mediated transfer of the interferon-gamma gene. In this trial, 11 patients were
treated with increasing vector doses. One grade 3 toxicity was observed and one patient
showed stable disease [91]. Matsumoto et al [92] report the use of cationic liposomes complexed
with a plasmid encoding the human interferon-beta gene in patients with metastatic melano‐
ma. There were no recognized adverse events and 1 (of 5) patients showed mixed response [92].
Our own laboratories are actively developing novel tools for gene therapy of cancer, including
melanoma. Since some 90% of melanoma cases retain wild type p53 [93], we reason that the
endogenous p53 protein may be re-activated and induced to participate in the treatment
scheme. To this end, we have developed viral vectors where the expression of the transgene
is regulated by the transactivation function of p53. We have shown that these vectors offer
superior levels of transgene expression [94-96] and the use of p53 or its functional partner, Arf
(p14Arf in humans, p19Arf in mice) creates a positive feedback loop [95, 97]. That is to say,
transgene function elevates p53 activity which, in turn, promotes expression from the vector
and so on. Our published data show that p19Arf, when delivered by our p53-responsive vector,
resulted in the sensitization of B16 mouse melanoma cells to pharmacologic agents both in
vitro and in vivo [97]. In our unpublished data, we have combined the activities of the p53/Arf
axis with intereferon-β. Though studies are ongoing, we have seen that the combined, but not
individual, gene therapies induce massive cell death both in vitro and in vivo. In addition,
immune protection is induced by either in situ tumor treatment or by a whole cell vaccine
transduced by the gene combination.
15. Conclusion
We have cited several, but certainly not all, examples of how gene therapy is advancing for
the treatment of melanoma. Though much has been learned, a long road remains before major
successes can be had. As with any experimental approach, progress is incremental and may
rely on joining distinct technologies. For example, the history of melanoma gene therapy
actually coincides with therapies for immune disorders. But, by daring to test new therapeutic
strategies, gene therapy of melanoma has paved the way for cancer gene therapy in general.
The future advances in melanoma gene therapy may come from combining pharmacologic
and genetic approaches. For example, the vectors mentioned above may be used in combina‐
tion with monoclonal antibodies (such as ipilumimab), small molecule inhibitors (such as
vermuafenib, PLK4032, the inhibitor of BRAF) and chemotherapies (such as dacarbazine).
Though much work remains to be done, it stands to reason that maximizing cell death and the
anti-tumor immune response should offer hope for future treatments of melanoma.
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